Bone allografts are commonly used for the repair of critical-size bone defects. However, the loss of cellular activity in processed grafts markedly reduces their healing potential compared with autografts. To overcome this obstacle, we developed a healing system for critical-size bone defects that consists of overlaying an implanted bone graft with a collagen sheet (CS) loaded with basic fibroblast growth factor (bFGF) fused to the collagen-binding domain derived from a Clostridium histolyticum collagenase (CB-bFGF). In a murine femoral defect model, defect sites treated with CS/CB-bFGF had a significantly larger callus volume than those treated with CS/native bFGF. In addition, treatment with CS/CB-bFGF resulted in the rapid formation of a hard callus bridge and a larger total callus volume at the host-graft junction than treatment with CS/bFGF. Our results suggest that the combined use of CS and CB-bFGF helps accelerate the union of allogenic bone grafts.
Irregular antibodies are non-ABO alloantibodies that can cause hemolytic disease in fetuses and newborns, reduced red cell survival, and delayed hemolytic transfusion reaction (DHTR). DHTR may present with intravascular hemolysis and associated findings, including death. However, little is known about the frequency of irregular antibodies in critically ill patients. Methods: We used an electronic clinical transfusion management system to retrospectively assess all patients who underwent irregular antibody screening between January 2012 and November 2015. We collected information about age, sex, transfusion history, and type of irregular antibodies. Results: Screening for irregular antibodies revealed that 14 (1.8%) of 770 patients (male, n=11; female, n=3; mean age [ ± SD], 64.0 ± 14.7 years) harbored irregular antibodies. Ten patients (1.3%) had clinically significant warm antibodies. Five patients had a history of transfusion and four did not. Information about transfusion was unavailable for the remaining five due to varying circumstances such as patient unconsciousness. Conclusion: Patients with irregular antibodies are not rare, and 14 (1.8%) of 770 patients in our ICU had them. As the history of transfusion in critically ill patients is often unknown, side effects of transfusion can be serious. Therefore, repeating irregular antibodies tests proactively may prevent side effects of transfusion, including DHTR.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.